Physician

Howard H Cheng, M.D.

According to 2025 Medicare claims, Howard Cheng, M.D. (NPI: 1366435299) practices hematology/oncology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. Cheng uses personal NPI as billing NPI and primary practice location at 92653-4341.

Cheng's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 457 traditional Medicare patients, billed 137,767 HCPCS/CPT codes, and received $1,620,654 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,152 prescription claims across 149 beneficiaries totaling $4,124,048 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 30 claims. Open Payments data shows 35 records totaling $893. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,945,625 and ending at $1,620,654. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,643,769 to $4,124,048. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	600	158,370	$1,945,625
2016	614	126,990	$2,095,737
2017	597	182,670	$2,837,333
2018	566	147,552	$2,273,239
2019	520	136,424	$1,698,079
2020	530	179,523	$2,045,164
2021	501	174,791	$2,567,303
2022	507	151,901	$2,170,997
2023	466	114,900	$2,112,947
2024	457	137,767	$1,620,654

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	154	1,084	$1,643,769
2016	183	1,190	$2,386,616
2017	203	1,507	$3,627,588
2018	204	1,470	$3,512,910
2019	195	1,416	$4,564,066
2020	184	1,412	$5,650,238
2021	174	1,436	$6,994,444
2022	186	1,383	$6,515,514
2023	173	1,184	$5,155,620
2024	149	1,152	$4,124,048

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	68	$46,683
2016	N/R	32	$17,873
2017	N/R	108	$26,739
2018	N/R	112	$11,601
2019	N/R	68	$9,465
2020	N/R	74	$4,171
2021	N/R	104	$4,142
2022	N/R	65	$1,625
2023	N/R	95	$19,404
2024	N/R	30	$918

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	95	478	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	410	900	$108
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	119	418	$13
36415	Insertion of needle into vein for collection of blood sample	362	1,337	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	361	1,536	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	42	1,260	$557,719
Imbruvica	Ibrutinib	29	812	$490,941
Pomalyst	Pomalidomide	24	672	$490,470
Lenalidomide	Lenalidomide	31	826	$415,241
Xtandi	Enzalutamide	21	630	$308,635

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$692
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$893	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Howard H. Cheng, M.D.?

Tedicare shows public-source Medicare data for Howard H. Cheng, M.D. (NPI 1366435299), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Howard H. Cheng, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Howard H. Cheng, M.D.?

A separate primary affiliated billing organization is not shown for this profile in the available data.

Does Howard H. Cheng, M.D. have Open Payments data?

Howard H. Cheng, M.D. has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.